EMEA-001864-PIP02-19

Key facts

Invented name
Takhzyro
Active substance
lanadelumab
Therapeutic area
Other
Decision number
P/0140/2020
PIP number
EMEA-001864-PIP02-19
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of acquired angioedema attacks
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Takeda Pharmaceuticals International AG Ireland Branch

E-mail: medinfoemea@takeda.com
Tel: +44 (0) 3333 000181

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating